Good news for a change from the NY Times:

"A drug already in widespread use to prevent bone thinning in women
past menopause can also reduce their risk of invasive breast cancer,
researchers reported yesterday.

The drug is raloxifene, sold as Evista, which half a million American
women take for osteoporosis. It is the second drug found to reduce the
risk of breast cancer. The first was tamoxifen, whose brand name is
Nolvadex, which is approved to treat breast cancer and also prevent it
in women at high risk for the disease.

A study sponsored by the National Cancer Institute has found that
raloxifene works as well as tamoxifen in women at high risk for
invasive breast cancer, and it may have fewer side effects. In those
cases, each drug halves the risk.
By DENISE GRADY
Published: April 18, 2006"
http://tinyurl.com/ql6uf